SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Brown E, Heerspink HJL, Cuthbertson DJ, et al.
Lancet. 2021;398(10296):262-276
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
A guideline for the outpatient management of glycaemic control in people with cancer
Joharatnam-Hogan N, Chambers P, Dhatariya K, et al.
Diabet Med. 2021;e14636.
Leggi
Echocardiographic predictors of long‐term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow‐up analysis of the Copenhagen City Heart Study
Özbek BT, Modin D, Møgelvang R, et al.
Diabet Med. Pub. online 12 July 2021
Leggi
Usefulness of glucagon-like peptide-1 receptor agonists to reduce adverse cardiovascular disease events in patients with type 2 diabetes mellitus
Grewal S, Zaman N, Borgatta L, et al.
Am J Cardiol. 2021;S0002-9149(21)00522-1.
Leggi
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Frías JP, Davies MJ, Rosenstock J, et al.
N Engl J Med. Pub. online 25 June 2021.
Leggi
Cholesterol control for subclinical coronary atherosclerosis in subjects without indication for statin therapy
Park HW, Kim YG, Park GM, et al.
Am J Cardiol. 2021;S0002-9149(21)00493-8.
Leggi
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein HC, Sattar N, Rosenstock J, et al.
NEJM. Pub. online 28 June 2021.
Leggi
Potentially modifiable risk factors of preterm delivery in women with type 1 and type 2 diabetes.
Søholm, JC, Vestgaard M, Ásbjörnsdóttir B, et al.
Diabetologia. Pub. online 19 Jun 2021.
Leggi
Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study
Jacobson AM, Ryan CM, Braffett BH, et al.
Lancet Diabetes Endocrinol. 2021;9(7):436-445.
Leggi
Diabetes technology use for management of type 1 diabetes is associated with fewer adverse covid-19 outcomes: findings from the T1D Exchange COVID-19 Surveillance Registry
Noor N, Ebekozien O, Levin L, et al.
Diabetes Care. 2021;dc210074.
Leggi